Pharmaceutical companies involved in the production of mifepristone, a key medication in abortion procedures, are seeking emergency relief from a recent court ruling that blocked the FDA's expansion of telemedicine access to the drug. The U.S. Court of Appeals for the Fifth Circuit's decision effectively reverses a long-standing policy change that allowed patients to receive prescriptions for mifepristone remotely, rather than in-person visits to a doctor. The FDA's rule, implemented in 2022, aimed to increase access to reproductive healthcare, particularly in rural areas where in-person consultations may be difficult to obtain. As the debate over abortion access continues, the pharmaceutical industry's push for interim relief raises questions about the balance between regulatory flexibility and judicial oversight.
Drug makers seek interim relief after the U.S. Court of Appeals for the Fifth Circuit blocks FDA rule allowing mifepristone prescriptions via telemedicine.
